RONALD LEVY, MD
Osteopathic Medicine at Pasteur Dr, Palo Alto, CA
License number
California G21994
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 723-4000
Organization information
See more information about RONALD LEVY at bizstanding.comStanford Univ-Oncology - Ronald Levy MD
269 Campus Dr #1105, Stanford, CA 94305
Categories:
Oncology Physicians & Surgeons
Site:
Phone:
(650) 725-6452 (Phone)
Ronald Levy MD
269 Campus Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 725-6452 (Phone)
Ronald A. Levy
Professional information
Ronald Levy, Stanford CA
Specialties:
Internist
Address:
300 Pasteur Dr, Stanford, CA 94305
Education:
Stanford University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Ronald A Levy, Stanford CA
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Stanford University
269 Campus Dr, Stanford, CA 94305 Stanford University
300 Pasteur Dr, Palo Alto, CA 94304 Lymphoma Clinic
875 Blake Wilbur Dr, Stanford, CA 94305 Lymphoma
875 Blake Wilbur Dr, Palo Alto, CA 94304
269 Campus Dr, Stanford, CA 94305 Stanford University
300 Pasteur Dr, Palo Alto, CA 94304 Lymphoma Clinic
875 Blake Wilbur Dr, Stanford, CA 94305 Lymphoma
875 Blake Wilbur Dr, Palo Alto, CA 94304
Education:
Stanford University (1968)
Transduced Neoplastic Cell Preparations Able To Express T-Cell Costimulatory Molecules B7.1, Icam-1, And Lfa-3 And Induce Immunostimulatory Prophylactic And Therapeutic Anti-Tumor Effects In-Vivo
US Patent:
2004010, May 27, 2004
Filed:
Sep 11, 2003
Appl. No.:
10/660369
Inventors:
Dennis Panicali - Acton MA, US
Ronald Levy - Stanford CA, US
Ronald Levy - Stanford CA, US
International Classification:
A61K048/00, C12N005/08
US Classification:
424/093210, 435/366000
Abstract:
The present invention provides a neoplastic cell transduced by a TRICOM viral vector construct and a genetically altered neoplastic cellular preparation able to overexpress molecule B7.1, intracellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-3 (LFA-3) as discrete products and costimulatory molecules. The TRICOM transduced neoplastic cells are useful in-vivo as a prophylactic vaccination to prevent the future generation of a tumor within a living mammalian subject; and also as a therapeutic anti-tumor agent effective against a pre-existing tumor then located at one or more anatomic sites within the body of a living mammalian patient.
Monoclonal Anti-Idiotype Antibodies
US Patent:
4816249, Mar 28, 1989
Filed:
Feb 19, 1987
Appl. No.:
7/016281
Inventors:
Ronald Levy - Stanford CA
Jeanette Dilley - Mt. View CA
David G. Maloney - Mt. View CA
Richard A. Miller - Palo Alto CA
Jeanette Dilley - Mt. View CA
David G. Maloney - Mt. View CA
Richard A. Miller - Palo Alto CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39395
US Classification:
424 858
Abstract:
Monoclonal anti-idiotype antibodies against cell surface Ig of human B-cell tumors, labeled conjugates of such antibodies, immunotherapeutic compositions containing such antibodies, and a process for making such antibodies. The nodular lymphoma of a patient treated with a monoclonal anti-idiotype antibody against the cell surface IgM of the patient's tumor went into complete remission.
Receptor-Binding Antiproliferative Peptides
US Patent:
5512435, Apr 30, 1996
Filed:
Feb 5, 1993
Appl. No.:
8/014426
Inventors:
Markus F. Renschler - Redwood City CA
Ronald Levy - Stanford CA
Ramesh R. Bhatt - Mountain View CA
William J. Dower - Menlo Park CA
Ronald Levy - Stanford CA
Ramesh R. Bhatt - Mountain View CA
William J. Dower - Menlo Park CA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
Methods and composition are provided for identifying antiproliferative polypeptides which inhibit clonal expansion and/or induce apoptosis in cells of a predetermined cell population (e. g. , a neoplastic cell sample) expressing a cell surface receptor which is a member of the immunoglobulin superfamily. A predetermined cell population expressing surface immunoglobulin superfamily molecules is isolated from a patient as a cellular sample, such as a lymph node biospy or blood sample containing neoplastic lymphocytic cells. Antiproliferative peptides which are identified by the methods of the invention can be used as therapeutic agents for treating lymphoproliferative disorders by anti-idiotype therapy.
Enhancement Of B Cell Lymphoma And Tumor Resistance Using Idiotype/Cytokine Conjugates
US Patent:
6099846, Aug 8, 2000
Filed:
Apr 14, 1995
Appl. No.:
8/416787
Inventors:
Ronald Levy - Stanford CA
Mi-Hua Tao - Taipei, TW
Mi-Hua Tao - Taipei, TW
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39385
US Classification:
42419511
Abstract:
B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This immuno-complex elicits immune responses which are protective with respect to tumor proliferation. The linkers may be simple chemical bifunctional moieties introduced through chemical synthetic techniques or peptides introduce through recombinant methodologies. Antibodies immunoreactive with these immunocomplexes are also useful as passive vaccines and as analytical tools.
Methods And Compositions For Determining Responsiveness To Antibody Therapy
US Patent:
2006000, Jan 12, 2006
Filed:
Jun 16, 2005
Appl. No.:
11/155308
Inventors:
Ronald Levy - Stanford CA, US
Wen-Kai Weng - Saratoga CA, US
Wen-Kai Weng - Saratoga CA, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435006000, 435007100
Abstract:
Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable FcγR polymorphism, e.g., the 131 H/H genotype or the 158 V/V genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.
Monoclonal Anti-Idiotype Antibodies
US Patent:
4661586, Apr 28, 1987
Filed:
Dec 2, 1983
Appl. No.:
6/557655
Inventors:
Ronald Levy - Stanford CA
Jeanette Dilley - Mt. View CA
David G. Maloney - Mt. View CA
Richard A. Miller - Palo Alto CA
Jeanette Dilley - Mt. View CA
David G. Maloney - Mt. View CA
Richard A. Miller - Palo Alto CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
C07K 300, C07K 1500, C12N 1500, G01N 3353
US Classification:
530387
Abstract:
Monoclonal anti-idiotype antibodies against cell surface Ig of human B-cell tumors, labeled conjugates of such antibodies, immunotherapeutic compositions containing such antibodies, and a process for making such antibodies. The nodular lymphoma of a patient treated with a monoclonal anti-idiotpye antibody against the cell surface IgM of the patient's tumor went into complete remission.
Methods And Compositions For Determining Neoplastic Disease Responsiveness To Antibody Therapy
US Patent:
2003021, Nov 27, 2003
Filed:
May 9, 2003
Appl. No.:
10/435508
Inventors:
Sean Bohen - Mountain View CA, US
Ronald Levy - Stanford CA, US
David Botstein - Belmont CA, US
Patrick Brown - Stanford CA, US
Ronald Levy - Stanford CA, US
David Botstein - Belmont CA, US
Patrick Brown - Stanford CA, US
International Classification:
C12Q001/68, G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
Methods are provided for determining whether a subject suffering from a neoplastic condition, e.g., non-Hodgkin's lymphoma (NHL), such as follicular lymphoma, is responsive to antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, an expression profile is obtained from the subject suffering from NHL and employed to determine whether the subject is responsive to antineoplastic therapy. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
Design Of Therapeutics And Therapeutics
US Patent:
2006001, Jan 26, 2006
Filed:
Jan 10, 2005
Appl. No.:
11/032773
Inventors:
Dana Ault-Riche - Los Gatos CA, US
Ronald Levy - Stanford CA, US
Ronald Levy - Stanford CA, US
International Classification:
A61K 39/395, C07K 16/46
US Classification:
424178100, 435188500, 530391100
Abstract:
Therapeutic complexes and components of therapeutic complexes are provided herein. Also provided are methods of preparing therapeutic complexes and methods of administering therapeutic complexes.